Bioactivity Analysis of Chalcone-Derived Compounds Based on In-Silico Molecular Docking Study
DOI:
10.29303/jpm.v20i2.8550Published:
2025-03-17Issue:
Vol. 20 No. 2 (2025): March 2025 - in ProgressKeywords:
Bioactivity; Chalcone; Derived; Molecular DockingArticles
Downloads
How to Cite
Downloads
Metrics
Abstract
Chalcone compounds are aromatic ketones and enones that have been found to have several activities, such as antimalarial, antioxidant, anti-inflammatory, anticancer, antiviral, anti-HIV, antifungal, antihyperglycemic, and carboxygenase inhibitors. A ligand's bioactivity can be predicted through in-silico tests using molecular docking. Molecular docking studies are conducted to study the interaction between ligand and receptor and identify the receptor's active site that matches the ligand when the ligand and receptor bind in a stable complex. This study can be a preliminary test before conducting in vitro and in vivo tests. This narrative review aims to analyze information on the bioactivity of chalcone-derived compounds and their derivatives through an in silico molecular docking approach in the form of binding affinity values and amino acid residues that bind. The method used is a literature study of 13 research articles found through the Semantic Scholar and Springer Link databases. The review results showed that the new compounds derived from chalcone compounds have a good range of bioactivity, as seen from the binding affinity values, which show lower values when compared to other test ligands and referenced ligands. The functional groups that have an important role in the interaction between ligands and proteins between ligands and receptors are triazole, methoxy, amine, halogen, carbonyl, hydroxyl, and thiol groups bound to the reactive structure of the α,β unsaturated ketone aromatic ring in the structure of the chalcone compound. The compounds that show promising activity can be further investigated as new drug candidates.
References
A. Rammohan, J. S. Reddy, G. Sravya, C. N. Rao, and G. V. Zyryanov, “Chalcone synthesis, properties and medicinal applications: a review”, Environ Chem Lett, vol. 18, no. 2, pp. 433–458, Mar. 2020, doi: 10.1007/s10311-019-00959-w.
A. Rammohan, J. S. Reddy, G. Sravya, C. N. Rao, and G. V. Zyryanov, “Chalcone synthesis, properties and medicinal applications: a review”, Environ Chem Lett, vol. 18, no. 2, pp. 433–458, Mar. 2020, doi: 10.1007/s10311-019-00959-w.
A. Mulula, A. Bouzina, H. Mambu, G. Mbiye, and A. Zaki, “Synthesis, in-vitro antitubercular, antifungal activities and in silico molecular docking study of Chalcone derivatives from 1-(2”-Hydroxyphenyl)-3-(substituted-phenyl)-2-propenone.”, Microbes and Infectious Diseases, vol. 0, no. 0, pp. 0–0, Feb. 2023, doi: 10.21608/mid.2023.191321.1458.
Dr. A. P. Desai and P. D. K, “Synthesis of Chalcone Derivatives and its Antimicrobial Activities”, IJSREM, vol. 07, no. 11, pp. 1–11, Nov. 2023, doi: 10.55041/IJSREM27306.
J. Syahri et al., “Chalcone Mannich base derivatives: synthesis, antimalarial activities against Plasmodium knowlesi , and molecular docking analysis”, RSC Adv., vol. 13, no. 51, pp. 36035–36047, 2023, doi: 10.1039/D3RA05361J.
I. Ikhtiarudin, L, A. Zamri, H. Y. Teruna, and Y. -, “SINTESIS DAN UJI TOKSISITAS SENYAWA ANALOG KALKON TURUNAN 2”-HIDROKSIASETOFENON DAN HALOBENZALDEHID”, Journal Photon, vol. 5, no. 1, pp. 57–63, Oct. 2014, doi: 10.37859/jp.v5i1.194.
Lusrianti, Balatif N, Zamri A. “Sintesis Dan Uji Toksisitas Senyawa Analog Kalkon Dari 4”- Hidroksiasetofenon Dengan Dimetoksibenzaldehid”. Journal Photon, vol. 6, no 01, pp 45¬–49, April. 2015, doi: 10.37859/jp.v6i01.462.
N A. A. T. Naqvi, T. Mohammad, G. M. Hasan, and Md. I. Hassan, “Advancements in Docking and Molecular Dynamics Simulations Towards Ligand-receptor Interactions and Structure-function Relationships”, CTMC, vol. 18, no. 20, pp. 1755–1768, Dec. 2018, doi: 10.2174/1568026618666181025114157.
P. A. Ravindranath, S. Forli, D. S. Goodsell, A. J. Olson, and M. F. Sanner, “AutoDockFR: Advances in Protein-Ligand Docking with Explicitly Specified Binding Site Flexibility”, PLoS Comput Biol, vol. 11, no. 12, p. e1004586, Dec. 2015, doi: 10.1371/journal.pcbi.1004586.
S. Al-Hazmy, M. Zouaghi, N. Amri, Y. Arfaoui, I. Alhagri, and N. Hamdi, “DFT Study of Regio- and Stereoselective 13DC Reaction between Diazopropane and Substituted Chalcone Derivatives: Molecular Docking of Novel Pyrazole Derivatives as Anti-Alzheimer”s Agents”, Molecules, vol. 28, no. 4, p. 1899, Feb. 2023, doi: 10.3390/molecules28041899.
S. Agarwal and R. Mehrotra, “An overview of Molecular Docking”, JSM Chem, vol. 4, no. 2, pp. 1024, May. 2016,
X. Du et al., “Insights into Protein–Ligand Interactions: Mechanisms, Models, and Methods”, IJMS, vol. 17, no. 2, p. 144, Jan. 2016, doi: 10.3390/ijms17020144.
M. B. Gurdere, Y. Budak, U. M. Kocyigit, P. Taslimi, B. Tüzün, and M. Ceylan, “ADME properties, bioactivity and molecular docking studies of 4-amino-chalcone derivatives: new analogues for the treatment of Alzheimer, glaucoma and epileptic diseases”, In Silico Pharmacol., vol. 9, no. 1, p. 34, May 2021, doi: 10.1007/s40203-021-00094-x.
A. S. Fitriana and S. Royani, “Molecular Docking Study of Chalcone Derivatives as Potential Inhibitors of SARS-CoV-2 Main Protease”, Indo. J. Chem. Res., vol. 9, no. 3, pp. 150–162, Jan. 2022, doi: 10.30598//ijcr.2022.9-fit.
M. A. Kurniawan and M. J. Baari, “Qsar Analysis Using Semi-Empirical Am1 Method, Molecular Docking, and Admet Studies of Chalcone Derivatives as Antimalarial Compounds”, Jurnal Kimia Riset, vol 8, no 2, pp. 186-199, Dec. 2023, doi: 10.20473/jkr.v8i2.51798.
A. Mulula, A. D. Bouzina, J. Nsomue, H. B. Mambu, M. N. Tshingamb, and A. Zaki. “Synthesis, In-vitro Antimalarial Activity and In silico Molecular Docking Study of Amino Chalcone Derivatives from 1-(2-aminophenyl)-3-(4-substituted-phenyl) prop-2-en-1-one and Dihydroquinolone Derivatives.” Journal of Advanced Pharmacy Research, vol 7, no 3, pp. 133-143, May. 2023, doi: 10.21608/aprh.2023.207345.1217.
G. Çelik, G. T. Yılmaz, B. Barut, C. Ö. Yalçın, and N. Yaylı. “Design, Synthesis, Biological Activity and Molecular Docking Studies of New Imine-Chalcone Derivatives.” Pharmaceutical Chemistry Journal, Vol 57, no 4, pp. 550-558, Jul. 2023, doi: 10.1007/s11094-023-02919-9.
A. A. Alman, V. Soni, and S. G. Killedar. “Molecular Docking, Synthesis and Biological Evaluation of Some Imidazo-thiadiazole Based Chalcone Derivatives as Potent Triple Mutant T790M/C797S EGFR Inhibitors.” International journal of health sciences, vol 6, no. S2, pp. 14410-14439, Jun. 2022. doi:10.53730/ijhs.v6nS2.8781.
B. Fegade and S. Jadhav. “Design, synthesis and molecular docking study of N-heterocyclic chalcone derivatives as an anti-cancer agents.” International Journal of Pharmaceutical Sciences and Drug Research, vol 14, no. 01, pp. 78-84, Jan. 2022. doi: 10.25004/IJPSDR.2022.140111.
Y. S. Kurniawan, E. Yudha, G. Nugraha, N, Fatmasari, H. D. Pranowo, J. Jumina, and E. N. Sholikhah. “Molecular Docking and Molecular Dynamic Investigations of Xanthone-Chalcone Derivatives against Epidermal Growth Factor Receptor for Preliminary Discovery of Novel Anticancer Agent.” Indonesian Journal of Chemistry, vol 24, no. 1, pp. 250-266, Nov. 2024. DOI: 10.22146/ijc.88449.
S. Farooq, Z. Ngaini, S. S. Hwang, D. C. Choo, A. I. Daud, and W. M. Khairul. “In vitro Cytotoxic Activities, Molecular Docking and Density Functional Theory (DFT) Evaluation of Chalcone Derived Pyrazolines.” Chemistry Africa, vol. 5, no. 2, 227-236, Jan. 2022. DOI: 10.1007/s42250-021-00311-2.
H. Kaur, R. Singh, and Rishikant. “Synthesis, molecular docking, and antitubercular evaluation of triazole–chalcone conjugates.” Russian Journal of Organic Chemistry. vol. 58, no. 4, pp. 518-525, June. 2022. DOI: 10.1134/S107042802204008X.
Y. T. Reubun, S. Kumala, S. Setyahadi, and P. Simanjuntak. “Penghambatan Enzim Asetilkolinesterase dari Ekstrak Herba Pegagan (Centella asiatica (L.) Urb), Ekstrak Daun Kelor (Moringa oleifera Lam.) dan Kombinasinya.” PHARMACY: Jurnal Farmasi Indonesia, vol. 17, no. 2, pp. 451-458, Dec. 2020. DOI: 10.30595/pharmacy.v17i2.9052
H. L. Qin, Z. W. Zhang, R. Lekkala, H. Alsulami, and K. P. Rakesh. “Chalcone hybrids as privileged scaffolds in antimalarial drug discovery: A key review.” European journal of medicinal chemistry, vol. 193, pp. 112215, Mar. 2020. DOI: 10.1016/j.ejmech.2020.112215.
Y. Suryani, O. Taupiqurrohman, A. Rikani, and E. Paujiah. “Insilico docking studies of daidzeion compounds as selective estrogen receptor modulator (SERMS) breast cancer EDP Sciences.” In MATEC Web of Conferences. vol 197, no. 03009, pp. 5, Sept 2018. DOI: 10.1051/matecconf/201819703009.
J.Y. Lim and P. D. Beer. “Sigma-Hole Interactions in Anion Recognition.” Chem, vol 4, no.4, pp. 73, Apr. 2018. DOI: 10.1016/j.chempr.2018.02.022.
S. Zolghadri, A. Bahrami, K. M. Hassan, M. J. Munoz, M. F. Garcia, C. F. Garcia, and A. A. Saboury. “A comprehensive review on tyrosinase inhibitors.” Journal of enzyme inhibition and medicinal chemistry, vol. 34, no. 1, pp. 279-309, Jan. 2019. DOI: 10.1080/14756366.2018.1545767.
A. Dashputra, Y. Therkar, A. Balpande, N. Khanwani, A. Wasewar, G. C. Patil, ... and C. Ravikumar. “Evaluation of tamoxifen analogues as potential estrogen receptor alpha inhibitors for breast cancer treatment: A computational approach.” Journal of Molecular Liquids, vol. 414, pp. 126209, Nov. 2024. doi: 10.1016/j.molliq.2024.1262
A. E. Maennling, M. K. Tur, M. Niebert, T. Klockenbring, F. Zeppernick, S. Gattenlöhner, et al. “Molecular targeting therapy against EGFR family in breast cancer, progress and future potentials.” Cancers, vol. 11, no. 12, pp. 1826, Nov. 2019. DOI: 10.3390/cancers11121826.
I. Sahidin, B. Sadrun, N. S. Rahmatika, A. W. Yodha, A. Fristiohady, A. Sundowo, and S. Fajriah. “Phytochemical screening and antioxidant and cytotoxic activities of ethyl acetate subfractions of soft coral Nepthea sp. growing in Southeast Sulawesi.” Journal of Applied Pharmaceutical Science, vol. 13, no. 2, pp. 099-105, Feb. 2023. DOI: 10.7324/JAPS.2023.130211.
M. Fillah, D. Herawati, T. M. and Fakih. “Uji In-Silico Aktivitas Antikanker Kolorektal Senyawa Organosulfur Bawang Putih (Allium sativum L.) terhadap Protein Target COX-2.” Bandung Conference Series: Pharmacy. vol 2, no. 2, pp. 973-989, Aug. 2022. DOI: 10.29313/bcsp.v2i2.4703.
Z. Zhu, C. Chen, J. Zhang, F. Lai, J. Feng, G. Wu, et al. “Exploration and biological evaluation of 1, 3-diamino-7 H-pyrrol [3, 2-f] quinazoline derivatives as dihydrofolate reductase inhibitors.” Journal of Medicinal Chemistry, vol. 66, no. 20, pp. 13946-13967, Sep. 2023. DOI: 10.1021/acs.jmedchem.3c00891
A. K. Gupta, A. Singh, and S. Singh. “Glycogenomics of Mycobacterium tuberculosis.” Mycobact Dis, vol. 4, no .175, pp. 2161, Nov. 2014. DOI: 10.4172/2161-1068.1000175.
A. Sharma, A. K. Agrahari, S. Rajkhowa, and V. K. Tiwari, “Emerging impact of triazoles as anti-tubercular agent.” European Journal of Medicinal Chemistry, vol. 238, pp. 114454, Aug. 2022. doi: 10.1016/j.ejmech.2022.114454
S. A. Khan, K. Zia, S. Ashraf, R. Uddin, and Z. Ul-Haq. “Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach.” Journal of Biomolecular Structure and Dynamics, vol. 39, no. 7, pp. 2607-2616, Apr. 2020. DOI: 10.1080/07391102.2020.1751298.
S. Kumar and M. Choudhary. “Structure-based design and synthesis of copper (II) complexes as antivirus drug candidates targeting SARS CoV-2 and HIV.” New Journal of Chemistry, vol. 46, no. 15, pp. 7128-7143, Mar. 2022. DOI: 10.1039/D2NJ00703G.126209,
Author Biographies
Aldila Divana Sarie, Department of Pharmacy, Faculty of Health Sciences, Universitas Singaperbangsa Karawang
Marsah Rahmawati Utami, Department of Pharmacy, Faculty of Health Sciences, Universitas Singaperbangsa Karawang
License
Copyright (c) 2025 Aldila Divana Sarie, Marsah Rahmawati Utami
This work is licensed under a Creative Commons Attribution 4.0 International License.
The following terms apply to authors who publish in this journal:
1. Authors retain copyright and grant the journal first publication rights, with the work simultaneously licensed under a Creative Commons Attribution License 4.0 International License (CC-BY License) that allows others to share the work with an acknowledgment of the work's authorship and first publication in this journal.
2. Authors may enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., posting it to an institutional repository or publishing it in a book), acknowledging its initial publication in this journal.
3. Before and during the submission process, authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website), as this can lead to productive exchanges as well as earlier and greater citation of published work (See The Effect of Open Access).
